RSS   Newsletter   Contact   Advertise with us

Sangamo BioSciences appoints two to board

Staff Writer | Richmond, Ca., USA | July 3, 2017
Sangamo BioSciencesJuly 3, 2017, Richmond, Ca., USA - Sangamo BioSciences, a clinical stage biopharmaceutical company, announced the appointment of Roger Jeffs and Joseph S. Zakrzewski to the company's board of directors.
Roger Jeffs currently serves as a Senior Advisor to United Therapeutics Corp., where he worked for 18 years, most recently as President and co-CEO.

Dr. Jeffs has over 25 years of experience in the biopharmaceutical industry in R&D, clinical development, regulatory and medical affairs.

While at United Therapeutics, Dr. Jeffs led the clinical development, regulatory approval and commercialization of six rare disease products.

Prior to joining United Therapeutics, Dr. Jeffs held positions in clinical development at Amgen, Inc. and Burroughs Wellcome Co.

He currently serves as a member of the board of directors of Axsome Therapeutics and Dova Pharmaceuticals.

Dr. Jeffs received a B.A. in Chemistry from Duke University and his Ph.D. in Pharmacology from the University of North Carolina.

Joseph S. Zakrzewski has over 25 years of experience in the biopharmaceutical industry with senior leadership experience in R&D, supply chain and manufacturing operations, business development and commercialization.

From 2010 through 2013, Mr. Zakrzewski was Chairman and CEO of Amarin Pharmaceuticals, where he led the development and commercialization of the company's first product, Vascepa.

Mr. Zakrzewski previously served as a Venture Partner with Orbimed Advisors, a venture capital firm, and as Chairman, President and CEO of Xcellerex, a privately held company focused on the commercialization of its proprietary manufacturing technology for biotherapeutics and vaccines.

Earlier, he served as COO of Reliant Pharmaceuticals before its acquisition by GlaxoSmithKline in 2007 and held various executive positions at Eli Lilly & Company in the areas of R&D, manufacturing, finance and business development.

Mr. Zakrzewski currently serves as a member of the board of directors of various public and private companies, including Acceleron Pharma, Amarin Pharmaceuticals Insulet Corporation and Onxeo SA where he serves as Chairman.

Mr. Zakrzewski received a B.S. in Chemical Engineering and an M.S. in Biochemical Engineering from Drexel University, and an M.B.A. in Finance from Indiana University.